Agenus reports positive results from UNICORN colon cancer trial
Agenus Inc. (AGEN) reported positive Phase 2 UNICORN trial results for botensilimab and balstilimab in colon cancer. In pMMR/MSS patients, 36% achieved major pathologic response, 29% complete response. All dMMR/MSI-H patients responded, with 13 complete responses. No recurrences at 12 months. Agenus plans a Phase 3 trial.
How this was made
The 30-second read
Why it matters
The trial's high response rates provide a strong proof-of-concept, potentially de‑risking the upcoming Phase 3 ROBBIN trial and supporting future partnerships or financing.
Market read
First disclosure of robust Phase 2 data for a colon cancer immunotherapy, likely to influence Agenus valuation and sector sentiment.
What to watch
Small trial size and early-stage nature could limit immediate price impact.
Background
Agenus (NASDAQ:AGEN) is a biotech focused on immunotherapy. The UNICORN trial evaluated neoadjuvant botensilimab +/- balstilimab in resectable colon cancer.
Ticker impact
Agenus reported positive Phase 2 UNICORN colon cancer trial results with high response rates.
likely upward pressure as investors price in the promising efficacy data
Phase 2 results showing 100% major pathologic response in dMMR/MSI-H cohort and 36% response in MSS cohort are material for a biotech.
Market effects
Positive data may lift other immuno-oncology candidates and related biotech stocks.
US biotech sector could see modest gains.
Limited to oncology biotech investors.
Counterpoint
Skeptics may question durability of responses and lack of long-term survival data.
Key entities
- companyAgenus Inc.
Biotech company developing immuno‑oncology therapies.
- drugbotensilimab
Anti‑PD‑1 antibody under investigation.
- drugbalstilimab
Anti‑CTLA‑4 antibody combined with botensilimab.
